ImmunityBio Statistics
Total Valuation
ImmunityBio has a market cap or net worth of $7.13 billion. The enterprise value is $8.09 billion.
Important Dates
The last earnings date was Monday, November 9, 2026, before market open.
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ImmunityBio has 1.06 billion shares outstanding. The number of shares has increased by 20.61% in one year.
| Current Share Class | 1.06B |
| Shares Outstanding | 1.06B |
| Shares Change (YoY) | +20.61% |
| Shares Change (QoQ) | +1.03% |
| Owned by Insiders (%) | 27.79% |
| Owned by Institutions (%) | 20.28% |
| Float | 410.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 39.04 |
| Forward PS | 23.30 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 44.31 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.27
| Current Ratio | 4.27 |
| Quick Ratio | 3.96 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.31 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -30.37% |
| Return on Invested Capital (ROIC) | -70.52% |
| Return on Capital Employed (ROCE) | -53.62% |
| Weighted Average Cost of Capital (WACC) | 5.52% |
| Revenue Per Employee | $264,214 |
| Profits Per Employee | -$1.61M |
| Employee Count | 691 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 0.66 |
Taxes
| Income Tax | -126,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +230.05% in the last 52 weeks. The beta is 0.17, so ImmunityBio's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | +230.05% |
| 50-Day Moving Average | 8.48 |
| 200-Day Moving Average | 7.97 |
| Relative Strength Index (RSI) | 40.71 |
| Average Volume (20 Days) | 13,087,065 |
Short Selling Information
The latest short interest is 126.08 million, so 11.85% of the outstanding shares have been sold short.
| Short Interest | 126.08M |
| Short Previous Month | 122.95M |
| Short % of Shares Out | 11.85% |
| Short % of Float | 30.70% |
| Short Ratio (days to cover) | 8.32 |
Income Statement
In the last 12 months, ImmunityBio had revenue of $182.57 million and -$1.11 billion in losses. Loss per share was -$1.08.
| Revenue | 182.57M |
| Gross Profit | 180.36M |
| Operating Income | -274.16M |
| Pretax Income | -1.11B |
| Net Income | -1.11B |
| EBITDA | -257.72M |
| EBIT | -274.16M |
| Loss Per Share | -$1.08 |
Full Income Statement Balance Sheet
The company has $334.33 million in cash and $1.30 billion in debt, with a net cash position of -$961.77 million or -$0.90 per share.
| Cash & Cash Equivalents | 334.33M |
| Total Debt | 1.30B |
| Net Cash | -961.77M |
| Net Cash Per Share | -$0.90 |
| Equity (Book Value) | -1.15B |
| Book Value Per Share | -1.08 |
| Working Capital | 320.70M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$287.56 million and capital expenditures -$9.12 million, giving a free cash flow of -$296.69 million.
| Operating Cash Flow | -287.56M |
| Capital Expenditures | -9.12M |
| Depreciation & Amortization | 16.44M |
| Net Borrowing | 78.01M |
| Free Cash Flow | -296.69M |
| FCF Per Share | -$0.28 |
Full Cash Flow Statement Margins
| Gross Margin | 98.79% |
| Operating Margin | -150.16% |
| Pretax Margin | -607.89% |
| Profit Margin | n/a |
| EBITDA Margin | -141.16% |
| EBIT Margin | -150.16% |
| FCF Margin | n/a |
Dividends & Yields
ImmunityBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -20.61% |
| Shareholder Yield | -20.61% |
| Earnings Yield | -16.05% |
| FCF Yield | -4.16% |
Analyst Forecast
The average price target for ImmunityBio is $14.25, which is 112.69% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $14.25 |
| Price Target Difference | 112.69% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 124.51% |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ImmunityBio has an Altman Z-Score of -9.35 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.35 |
| Piotroski F-Score | 2 |